These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 10581603)

  • 1. Vaccine therapy for patients with melanoma.
    Haigh PI; Difronzo LA; Gammon G; Morton DL
    Oncology (Williston Park); 1999 Nov; 13(11):1561-74; discussion 1574 passim. PubMed ID: 10581603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma vaccines: what we know so far.
    Bystryn JC; Reynolds SR
    Oncology (Williston Park); 2005 Jan; 19(1):97-108; discussion 108, 111-2, 115. PubMed ID: 15743154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine therapy for melanoma: current status and future directions.
    Terando AM; Faries MB; Morton DL
    Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of malignant melanoma.
    Kadison AS; Morton DL
    Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma vaccines: early progress and future promises.
    Zarour HM; Kirkwood JM
    Semin Cutan Med Surg; 2003 Mar; 22(1):68-75. PubMed ID: 12773015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell vaccination as a treatment modality for melanoma.
    Eubel J; Enk AH
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
    Sondak VK; Sosman JA
    Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
    Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
    J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma vaccines.
    Chapman PB
    Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
    Morton DL
    Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccine strategies against melanoma].
    Ghiringhelli F; Zitvogel L
    Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging melanoma vaccines.
    Bystryn JC; Rudolph JL
    Expert Opin Emerg Drugs; 2005 May; 10(2):393-402. PubMed ID: 15934874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
    Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
    Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
    Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
    Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.